学术周报 · IF≥10 或专科旗舰刊
肾内科领域文献阅读汇编
2026年第47周 (2026-11-20) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Kidney international | 5 | IF 21.8 |
| American journal of kidney diseases : the official journal of the National Kidney Foundation | 5 | IF 9.4 |
| Journal of the American Society of Nephrology : JASN | 4 | IF 9.7 |
| Science advances | 2 | IF 13.9 |
| Cellular & molecular immunology | 1 | IF 23.9 |
| Drugs | 1 | IF 14.7 |
| Archives of toxicology | 1 | IF 10.9 |
| Pharmacological research | 1 | IF 12.2 |
| Clinical and molecular hepatology | 1 | IF 21.7 |
| JAMA internal medicine | 1 | IF 26.3 |
1慢性肾脏病 CKD (12篇)
临床研究 (7篇)
Endothelin-A receptor antagonists (ERAs) are emerging as an important treatment for proteinuric chronic kidney disease (CKD). As with renin-angiotensin-aldosterone system (RAAS) inhibition, dietary sodium intake may influence their therapeutic efficacy, but this has not been investigated. Here, we examined whether dietary sodium restriction enhances the systemic and kidney effects of acute selective endothelin-A (ETA) receptor antagonism in proteinuric CKD. In a randomized, double-blind, placebo-controlled crossover study, 12 adults (mean age 46 years) with non-diabetic proteinuric CKD (mean eGFR 55 mL/min/1.73 m2; median proteinuria 1.8 g/day) receiving maximally tolerated RAAS inhibition completed two 14-day dietary interventions (habitual dietary sodium intake [13.3 g salt/day] and dietary sodium restriction [6.3 g salt/day, approximating guideline-recommended levels]) in random order. During each dietary period, participants underwent two study visits and received intravenous infusion of either placebo or the selective ET A receptor antagonist, BQ123. Systemic hemodynamics, arterial stiffness, kidney hemodynamics and proteinuria were assessed following each intervention. BQ123 produced comparable reductions in systolic blood pressure (about 12-14 mmHg), systemic vascular resistance and arterial stiffness under both dietary conditions and increased kidney blood flow (about 320-335 mL/min) irrespective of dietary sodium intake. In contrast, significant reductions in glomerular filtration rate (peak placebo-adjusted reduction: about 5 mL/min/1.73 m2), effective filtration fraction (peak reduction about 1.5%), and proteinuria (about 300 μg/min) were observed only during dietary sodium restriction and not during habitual sodium intake. Dietary sodium restriction enhances the short-term kidney efficacy of selective endothelin-A receptor antagonism in proteinuric CKD while preserving its beneficial systemic hemodynamic effects. As ERAs become established therapies for proteinuric kidney disease, these findings suggest that adherence to dietary sodium restriction may maximize their kidney-protective benefits. Whether the acute changes demonstrated here translate into long-term kidney protection requires prospective evaluation.
中文摘要:内皮素A受体拮抗剂(ERAs)正成为治疗蛋白尿性慢性肾脏病(CKD)的重要手段。与肾素-血管紧张素-醛固酮系统(RAAS)抑制类似,饮食钠摄入量可能影响其疗效,但尚未得到研究。本研究探讨了饮食限钠是否增强急性选择性内皮素A(ETA)受体拮抗在蛋白尿性CKD中的全身及肾脏效应。在一项随机、双盲、安慰剂对照的交叉研究中,12名接受最大耐受剂量RAAS抑制的非糖尿病蛋白尿性CKD成人患者(平均年龄46岁;平均eGFR 55 mL/min/1.73 m2;中位蛋白尿1.8 g/day)按随机顺序完成了两种为期14天的饮食干预(习惯性钠摄入量[13.3 g盐/天]和限钠饮食[6.3 g盐/天,接近指南推荐水平])。在每个饮食期间,参与者进行了两次研究访视,并接受静脉输注安慰剂或选择性ETA受体拮抗剂BQ123。在每次干预后评估了全身血流动力学、动脉僵硬度、肾脏血流动力学和蛋白尿。无论饮食钠摄入量如何,BQ123均产生相似的收缩压降低(约12-14 mmHg)、全身血管阻力降低和动脉僵硬度改善,并增加肾血流量(约335 mL/min)。相比之下,仅在限钠期间观察到肾小球滤过率显著降低(峰值安慰剂校正后降低:约5 mL/min/1.73 m2)、有效滤过分数降低(峰值降低约1.5%)和蛋白尿减少(约300 μg/min),而在习惯性钠摄入期间未观察到这些变化。饮食限钠增强了选择性ETA受体拮抗在蛋白尿性CKD中的短期肾脏疗效,同时保留了其有益的全身血流动力学效应。随着ERAs成为蛋白尿性肾脏疾病的既定疗法,这些发现表明遵循饮食限钠可能最大化其肾脏保护益处。此处显示的急性变化是否转化为长期肾脏保护需要前瞻性评估。
Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH) impose a rapidly increasing hepatic and cardiometabolic burden worldwide and in Korea. Following the phase 3 ESSENCE trial, which demonstrated the histological efficacy of semaglutide in noncirrhotic MASH with fibrosis, practical guidance for routine clinical care is needed. The Korean Association for the Study of the Liver developed this expert consensus statement on semaglutide treatment in MASH. Using the RAND/UCLA Appropriateness Method, a 15-member expert panel rated 98 clinical scenarios covering patient selection, dosing, response assessment, adverse event management, and metabolic comorbidities over two rating rounds with a structured panel discussion. Semaglutide is primarily intended for patients with noncirrhotic MASH and stage 2-3 fibrosis. Eligibility should be assessed using a two-step strategy of age-adjusted Fibrosis-4 index screening followed by vibration-controlled transient elastography (VCTE). A VCTE-derived liver stiffness measurement (LSM) of 10-15 kPa defines the preferred treatment range; 15-20 kPa is acceptable when cirrhosis and portal hypertension are excluded, whereas 8-10 kPa requires repeat VCTE, magnetic resonance elastography (eligible range, 3.1-4.4 kPa), or liver biopsy. Semaglutide is initiated at 0.25 mg once weekly and escalated every 4 weeks to a target maintenance dose of 2.4 mg. Response should be assessed with noninvasive tests after at least 18 months; a ≥30% reduction in VCTE-derived LSM suggests response. This consensus provides a structured framework for semaglutide use in MASH, integrated with management of obesity, type 2 diabetes, cardiovascular risk, and chronic kidney disease.
中文摘要:代谢功能障碍相关脂肪性肝病和代谢功能障碍相关脂肪性肝炎(MASH)在全球及韩国造成日益增加的肝脏和心脏代谢负担。在证明司美格鲁肽对伴有纤维化的非肝硬化MASH具有组织学疗效的3期ESSENCE试验之后,临床常规护理需要实用指导。韩国肝脏研究协会制定了关于MASH治疗中司美格鲁肽使用的专家共识声明。该15人专家小组采用RAND/UCLA适宜性方法,经过两轮评分和结构化小组讨论,对涵盖患者选择、剂量调整、疗效评估、不良事件管理和代谢合并症的98个临床场景进行了评级。司美格鲁肽主要适用于伴有2至3期纤维化的非肝硬化MASH患者。资格评估应采用两步策略:首先是年龄调整的Fibrosis-4指数筛查,其次是振动控制瞬时弹性成像(VCTE)。VCTE衍生的肝脏硬度测量值(LSM)为10至15 kPa定义为首选治疗范围;在排除肝硬化和门静脉高压的情况下,15至20 kPa是可接受的,而8至10 kPa则需要重复VCTE、磁共振弹性成像(合格范围为3.1至4.4 kPa)或肝活检。司美格鲁肽起始剂量为每周一次0.25 mg,每4周递增一次,目标维持剂量为2.4 mg。疗效应在至少18个月后通过无创测试进行评估;VCTE衍生的LSM降低≥30%提示治疗有效。该共识为MASH中司美格鲁肽的使用提供了结构化框架,并与肥胖、2型糖尿病、心血管风险和慢性肾脏病的管理相结合。
The Centers for Medicare and Medicaid Services (CMS) adjusts for race and ethnicity when calculating and publicly reporting standardized mortality ratios (SMRs) of dialysis facilities. In July 2025, CMS removed race, ethnicity, and related demographic fields from the End-Stage Renal Disease Medical Evidence Report-the primary data source for race and ethnicity in SMR risk adjustment. To evaluate how removing race and ethnicity from SMR calculations is associated with facility-level performance, particularly among facilities serving high proportions of patients with social risk factors. In this cross-sectional study using the US Renal Data and Renal Management Information Systems, data from dialysis facilities in the US during the period of January 2017 to December 2020 were analyzed from October 2025 to January 2026. Facilities were categorized into quintiles based on the proportion of incident patients who were non-Hispanic Black, Hispanic, living in highly disadvantaged neighborhoods, or uninsured or Medicaid-covered at dialysis initiation. A composite social risk score classified facilities as being in the highest quintile of none, 1, or at least 2 of these characteristics. Race and ethnicity, socioeconomic status, and insurance coverage proportions of patients. The primary outcomes were change in facility-level SMR values and rankings after the removal of race and ethnicity from risk adjustment. Among 6895 dialysis facilities, 6220 (90.2%) were for profit, and 1588 (23.0%) had the highest social risk score of 2 or higher. With race-inclusive adjustment, the mean (SD) SMR among facilities with the lowest social risk was 0.93 (0.39), compared with 1.03 (0.42) among facilities with the highest social risk (difference, 0.10; 95% CI, 0.09-0.12). After removing race and ethnicity, this difference was nearly eliminated to -0.002 (95% CI, -0.02 to 0.01). A total of 1259 facilities (21.6%) with high social risk improved in SMR ranking after race exclusion, compared with 236 facilities (1.9%) with low social risk (difference, 19.7; 95% CI, 18.4-20.9 percentage points). Facilities serving the highest proportion of non-Hispanic Black patients experienced the greatest gains, with 26.6% improving SMR performance, compared with 4.7% among all other facilities (difference, 21.9; 95% CI, 20.5-23.3 percentage points). Results of this cross-sectional study suggest that removing race and ethnicity from SMR risk adjustment substantially altered publicly reported mortality performance among dialysis facilities, with the largest changes among facilities serving larger proportions of Black patients. These findings suggest that excluding race and ethnicity from SMR risk adjustment may meaningfully shift performance comparisons in favor of facilities serving populations with greater social risk.
中文摘要:美国医疗保险和医疗补助服务中心在计算并公开报告血液透析机构的标准化死亡率比值时,会对种族和民族进行调整。2025年7月,该中心从用于SMR风险调整的种族和民族主要数据来源终末期肾病医学证据报告中移除了种族、民族及相关人口统计字段。本研究旨在评估从SMR计算中移除种族和民族与机构层面绩效之间的关联,特别是服务于高比例社会风险因素患者的机构。这是一项横断面研究,利用美国肾脏数据和肾脏管理信息系统,分析了2017年1月至2020年12月期间美国透析机构的数据,分析时间为2025年10月至2026年1月。根据新发患者中非西班牙裔黑人、西班牙裔、居住在高劣势社区或透析启动时无保险/由医疗补助覆盖的比例,将机构分为五分位数。复合社会风险评分将机构分类为具有零、一个或至少两个上述特征的最高五分位数。研究关注患者的种族和民族、社会经济地位及保险覆盖比例。主要结局指标为从风险调整中移除种族和民族后,机构层面SMR数值和排名的变化。在6895家透析机构中,6220家(90.2%)为营利性机构,1588家(23.0%)具有最高社会风险评分2或更高。在包含种族调整的情况下,社会风险最低的机构平均SMR为0.93(标准差0.39),而社会风险最高的机构为1.03(标准差0.42),差异为0.10(95%置信区间0.09-0.12)。移除种族和民族后,这一差异几乎消除至-0.002(95%置信区间-0.02至0.01)。在排除种族后,1259家(21.6%)高社会风险机构的SMR排名有所改善,而低社会风险机构中仅有236家(1.9%)改善,差异为19.7个百分点(95%置信区间18.4-20.9)。服务非西班牙裔黑人患者比例最高的机构获益最大,26.6%的机构SMR表现有所改善,而其他所有机构中这一比例为4.7%,差异为21.9个百分点(95%置信区间20.5-23.3)。本横断面研究结果表明,从SMR风险调整中移除种族和民族显著改变了透析机构公开报告的死亡绩效,其中服务于黑人患者比例较高的机构变化最大。这些发现表明,在SMR风险调整中排除种族和民族可能使绩效比较更有利地倾向于服务社会风险较高人群的机构。
Although heat and humidity can affect kidney health, global evidence on the impact of heat on kidney-related mortality is sparse, and humidity's modifying role remains unquantified. This study aimed to examine the association between heat, humidity, and kidney-related mortality in 128 locations across 10 countries. To estimate the association between summer temperature and kidney-related mortality, a case time-series design was applied using a distributed lag nonlinear model with 10 lag days. Effect modification by humidity was assessed by adding an interaction term between temperature and humidity in the model. We further examined the association in three climate regions stratified by clustering method. The relative risk (RR) of total kidney disease-, acute kidney injury-, and chronic kidney disease-related mortality at the 99th (30.6℃) versus 75th (26.5℃) percentile of summer temperature was 1.07 (95% confidence interval [CI]: 1.04, 1.11), 1.13 (1.06, 1.21), and 1.01 (0.96, 1.07), respectively. The heat-mortality risk was more evident at high humidity than at low humidity: RR (95% CI) of total kidney disease at the 99th versus 75th percentile temperature was 1.10 (1.06, 1.14) and 1.05 (0.99, 1.11) at high and low humidity, respectively. The difference in RR between low and high humidity widened with increasing temperature, though CIs overlapped considerably. The suggestion of effect modification by humidity was more pronounced in cool-dry and humid tropical climate regions, but absent in the humid mid-latitude region. These findings suggest the need for region-specific preparedness against potential increase in kidney deaths in a future with rising temperature and humidity levels.
中文摘要:尽管高温和高湿可能影响肾脏健康,但关于高温对肾脏相关死亡率影响的全球证据仍然匮乏,且湿度在其中的修饰作用尚未量化。本研究旨在探讨10个国家128个地点的高温、高湿与肾脏相关死亡率之间的关联。为估算夏季温度与肾脏相关死亡率之间的关联,研究采用分布滞后非线性模型结合病例时间序列设计,滞后天数设为10天。通过在模型中加入温度与湿度的交互项来评估湿度对效应的修饰作用。我们进一步根据聚类方法划分的三个气候区域分析了这种关联。在夏季温度的第99百分位(30.6℃)与第75百分位(26.5℃)相比,总肾脏疾病、急性肾损伤和慢性肾脏病相关死亡的相对风险分别为1.07(95%置信区间:1.04, 1.11)、1.13(1.06, 1.21)和1.01(0.96, 1.07)。高温致死风险在高湿环境下比低湿环境更为显著:在高湿和低湿条件下,总肾脏疾病在第99百分位与第75百分位温度下的相对风险分别为1.10(1.06, 1.14)和1.05(0.99, 1.11)。随着温度升高,低湿与高湿之间的相对风险差异扩大,尽管置信区间存在较大重叠。湿度修饰效应的迹象在凉爽干燥和湿热热带气候区域更为明显,但在湿润中纬度区域则未观察到。这些发现表明,在未来温度和湿度水平上升的背景下,需要针对特定区域做好应对肾脏死亡增加的准备工作。
Mineralocorticoid receptor overactivation is implicated in podocyte injury and glomerulosclerosis. In a prespecified analysis of the FIND-CKD trial, we examined the efficacy and safety of finerenone in participants with focal segmental glomerulosclerosis (FSGS). The FIND-CKD trial randomized 1584 adults with nondiabetic CKD (eGFR ≥25 to <60 ml/min/1.73 m2 and urinary albumin-to-creatinine ratio [UACR] ≥200 to <500 mg/g, or eGFR ≥25 to <90 ml/min/1.73 m2 and UACR ≥500 to ≤3500 mg/g) on stable renin-angiotensin system inhibition, 1:1 to finerenone (10 or 20 mg) or placebo. Reported outcomes include total eGFR slope (baseline to month 32; FIND-CKD primary outcome), a kidney composite (sustained ≥57% eGFR decline from baseline or kidney failure; FIND-CKD secondary outcome), changes in urinary protein-to-creatinine ratio (UPCR; exploratory outcome), and adverse events (safety outcome). Among the 215 participants with FSGS, mean (SD) baseline eGFR was 45 (17) ml/min/1.73 m2, and median (Q1, Q3) UPCR was 1427 (947, 2120) mg/g; 50% each had primary (n=108) and secondary (n=107) FSGS. Finerenone reduced the total eGFR slope versus placeboby 1.3 ml/min/1.73 m2/year (95% CI, 0.5-2.2; P=0.002). This effect was consistent among the 167 (78%) participants with a biopsy-proven FSGS diagnosis (1.4 ml/min/1.73 m2/year), and among participants with primary or secondary FSGS (P-interaction 0.84). Finerenone yielded a hazard ratio of 0.58 (95% CI, 0.30-1.15) versus placebo for the kidney composite outcome. From baseline to month 12, finerenone lowered UPCR by 41% (95% CI, 26%-53%) versus placebo and increased the likelihood of achieving UPCR <700 mg/g (odds ratio at month 12: 6.8 [95% CI, 3.0-17.2]). A post hoc exploratory proteomics analysis showed that finerenone versus placebo reduced markers of fibrosis, inflammation, and components of the filtration barrier. Hyperkalemia-related adverse events occurred in 15 (15%) and 23 (20%) participants assigned to finerenone or placebo, respectively. Finerenone was well-tolerated and preserved kidney function, lowered proteinuria, and reduced markers of fibrosis, inflammation, and components of filtration barrier in FIND-CKD participants with FSGS.
中文摘要:盐皮质激素受体过度激活与足细胞损伤及肾小球硬化有关。在FIND-CKD试验的预设分析中,我们评估了非奈利酮在局灶节段性肾小球硬化(FSGS)受试者中的疗效和安全性。FIND-CKD试验将1584名接受稳定肾素-血管紧张素系统抑制治疗且符合特定估算肾小球滤过率(eGFR)及尿白蛋白肌酐比值(UACR)标准的非糖尿病慢性肾脏病成人患者,按1:1比例随机分配至非奈利酮组(10或20 mg)或安慰剂组。报告的结果包括总eGFR斜率(基线至第32个月;FIND-CKD主要结局)、肾脏复合终点(持续≥57%的eGFR下降或肾衰竭;FIND-CKD次要结局)、尿蛋白肌酐比值(UPCR)变化(探索性结局)以及不良事件(安全性结局)。在215名FSGS受试者中,平均(标准差)基线eGFR为45(17)ml/min/1.73 m2,中位数(四分位距)UPCR为1427(947, 2120)mg/g;其中原发性FSGS占50%(n=108),继发性FSGS占50%(n=107)。与非奈利酮相比,安慰剂组的总eGFR斜率降低了1.3 ml/min/1.73 m2/年(95% CI, 0.5-2.2;P=0.002)。在167名(78%)经活检证实FSGS诊断的受试者中,该效应一致(1.4 ml/min/1.73 m2/年),在原发性或继发性FSGS受试者中也保持一致(交互作用P值0.84)。与非奈利酮相比,安慰剂组的肾脏复合终点风险比为0.58(95% CI, 0.30-1.15)。从基线至第12个月,与非奈利酮相比,安慰剂组UPCR降低了41%(95% CI, 26%-53%),且实现UPCR <700 mg/g的可能性降低(第12个月比值比:6.8 [95% CI, 3.0-17.2])。事后探索性蛋白质组学分析显示,与非奈利酮相比,安慰剂组纤维化、炎症及滤过屏障成分的标志物水平升高。高钾血症相关不良事件在非奈利酮组和安慰剂组分别发生于15名(15%)和23名(20%)受试者中。在FIND-CKD试验的FSGS受试者中,非奈利酮耐受性良好,能保护肾功能、降低蛋白尿并减少纤维化、炎症及滤过屏障成分的标志物。
Islet transplantation alone (ITA) is an established treatment for severe hypoglycaemia in type 1 diabetes, requiring calcineurin inhibitor-based immunosuppression, which is associated with nephrotoxicity. These limitations have driven longstanding interest in calcineurin inhibitor-free strategies, which are now entering clinical translation. The aim of this study was to evaluate long-term kidney function in 223 adults (41% male) undergoing ITA at the University of Alberta Hospital (1999-2018) using eGFR. Mixed-effects models were used to assess eGFR decline rates (ml min-1 1.73 m-2 per year) stratified by sex and baseline eGFR. Acute eGFR changes were assessed within 3 months of each infusion. Univariate and multivariable Cox models and competing risk regression were used to identify factors associated with progression to stage 3b chronic kidney disease (CKD) or worse (eGFR <45 ml min-1 1.73 m-2) in individuals with baseline eGFR ≥45 ml min-1 1.73 m-2. eGFR declined rapidly in the first year post-transplant (-11.52 ml min-1 1.73 m-2 per year; 95% CI -13.92, -9.00), then stabilised, with decline rates of -3.12 (95% CI -3.84, -2.28) and -1.08 (95% CI -1.80, -0.36) ml min-1 1.73 m-2 per year at 1-5 and 5-20 years, respectively. Female recipients experienced a greater first-year decline than male recipients (-14.79 ml min-1 1.73 m-2 per year [95% CI -17.92, -11.66] vs -6.75 ml min-1 1.73 m-2 per year [95% CI -10.49, -3.01]; p=0.0012). Individuals with baseline eGFR <60 ml min-1 1.73 m-2 had a similar first-year decline compared to those with preserved function (-3.99 ml min-1 1.73 m-2 per year [95% CI -13.31, 5.33] vs -12.03 ml min-1 1.73 m-2 per year [95% CI -14.57, -9.49]; p=0.10). Progression to stage 3b CKD occurred in 21% of participants (47/222) over a median of 6.4 years. Female sex (sub-distribution HR 2.17; 95% CI 1.15, 4.17; p=0.017) and lower baseline eGFR (sub-distribution HR 0.96 per ml min-1 1.73 m-2; 95% CI 0.94, 0.98; p=0.0009) were independent predictors of progression. Although calcineurin inhibitor-based immunosuppression induces rapid early eGFR decline, its progression slows substantially beyond 5 years. Female sex and lower pre-transplant eGFR independently predicted CKD progression. This sex disparity remains to be fully understood, as male and female recipients did not differ in baseline eGFR or tacrolimus exposure. These findings establish a long-term renal safety benchmark within the largest and longest-running ITA programme, and identify subgroups who are most likely to benefit from emerging calcineurin inhibitor-free strategies.
中文摘要:胰岛移植(ITA)是治疗1型糖尿病严重低血糖的成熟疗法,需采用基于钙调磷酸酶抑制剂(CNI)的免疫抑制方案,该方案与肾毒性相关。这些局限性促使学界长期关注无CNI策略,目前正进入临床转化阶段。本研究旨在评估在阿尔伯塔大学医院接受ITA的223名成人(41%为男性,1999-2018年)的长期肾功能变化,采用估算肾小球滤过率(eGFR)作为指标。利用混合效应模型评估按性别和基线eGFR分层的eGFR下降速率(ml min-1 1.73 m-2/年)。在每次输注后3个月内评估急性eGFR变化。采用单变量和多变量Cox模型及竞争风险回归,识别与进展为3b期慢性肾脏病(CKD)或更严重阶段(eGFR <45 ml min-1 1.73 m-2)相关的因素,研究对象为基线eGFR ≥45 ml min-1 1.73 m-2的个体。移植后第一年eGFR迅速下降(-11.52 ml min-1 1.73 m-2/年;95% CI -13.92, -9.00),随后趋于稳定,第1至5年和第5至20年的下降速率分别为-3.12(95% CI -3.84, -2.28)和-1.08(95% CI -1.80, -0.36)ml min-1 1.73 m-2/年。女性受者的第一年下降幅度大于男性(-14.79 ml min-1 1.73 m-2/年 [95% CI -17.92, -11.66] vs -6.75 ml min-1 1.73 m-2/年 [95% CI -10.49, -3.01];p=0.0012)。基线eGFR <60 ml min-1 1.73 m-2的个体与肾功能保留者相比,第一年下降幅度相似(-3.99 ml min-1 1.73 m-2/年 [95% CI -13.31, 5.33] vs -12.03 ml min-1 1.73 m-2/年 [95% CI -14.57, -9.49];p=0.10)。中位随访6.4年间,21%的参与者(47/222)进展为3b期CKD。女性性别(亚分布HR 2.17;95% CI 1.15, 4.17;p=0.017)和较低的基线eGFR(亚分布HR 0.96 per ml min-1 1.73 m-2;95% CI 0.94, 0.98;p=0.0009)是进展的独立预测因子。尽管基于CNI的免疫抑制导致早期eGFR迅速下降,但5年后其进展显著放缓。女性性别和较低的术前eGFR独立预测CKD进展。这种性别差异尚未完全阐明,因为男性和女性受者在基线eGFR或他克莫司暴露量上无差异。这些发现确立了最大且运行时间最长的ITA项目的长期肾脏安全基准,并识别出最可能从新兴无CNI策略中受益的亚组。
Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are first-line treatment for hypertension in chronic kidney disease (CKD). However, guidelines do not recommend subsequent medication classes if additional blood pressure-lowering effect is desired. This target trial emulation using national outpatient data from the Veterans Health Administration from January 1, 2010, to December 31, 2016, included adults with non-dialysis CKD stages G1-G5 on an ACEi/ARB who initiated treatment with a second antihypertensive medication, classified as a thiazide diuretic, loop diuretic, calcium channel blocker, or β-blocker. Outcomes included composite cardiovascular events (fatal or nonfatal myocardial infarction or stroke, hospitalization for heart failure, coronary revascularization), all-cause death, and composite kidney outcomes (dialysis initiation, kidney transplantation, sustained creatinine doubling). Clinically important characteristics were included as covariates in the analysis. Of 150,369 individuals already on ACEi/ARB treatment, 45,836 (30%) were prescribed a thiazide diuretic, 17,589 (12%) a loop diuretic, 33,172 (22%) a calcium channel blocker, and 53,772 (36%) a β-blocker. Those receiving thiazide diuretics and calcium channel blockers had the highest baseline blood pressure. Those receiving loop diuretics were more likely to have more advanced CKD or heart failure. Over a median (IQR) follow-up of 1282 (621, 1979) days, compared to thiazide diuretics, cardiovascular event risk was higher for calcium channel blockers, aHR 1.18 (95% CI 1.15-1.22), β-blockers, aHR 1.63 (95% CI 1.58-1.67), and loop diuretics, aHR 1.97 (95% CI 1.90-2.04). Composite kidney outcomes were also higher with calcium channel blockers, aHR 1.42 (95% CI 1.33-1.52), β-blockers, aHR 1.13 (95% CI 1.06-1.21), and loop diuretics, aHR 1.98 (95% CI 1.83-2.15). Adding a thiazide diuretic rather than a calcium channel blocker, β-blocker, or loop diuretic on top of ACEi/ARB treatment was associated with favorable clinical outcomes among people with CKD.
中文摘要:血管紧张素转换酶抑制剂(ACEi)和血管紧张素受体阻滞剂(ARB)是慢性肾脏病(CKD)患者高血压的一线治疗药物。然而,若需进一步降低血压,指南并未推荐后续使用的药物类别。本研究利用2010年1月1日至2016年12月31日期间美国退伍军人健康管理局的国家门诊数据,模拟目标试验,纳入已接受ACEi或ARB治疗的非透析CKD G1-G5期成人患者,这些患者新启动了第二种抗高血压药物治疗,分类为噻嗪类利尿剂、袢利尿剂、钙通道阻滞剂或β受体阻滞剂。主要结局包括复合心血管事件(致命或非致命心肌梗死或卒中、心力衰竭住院、冠状动脉血运重建)、全因死亡以及复合肾脏结局(开始透析、肾移植、肌酐持续倍增)。分析中纳入了重要的临床特征作为协变量。在150,369名已接受ACEi/ARB治疗的患者中,45,836名(30%)被处方噻嗪类利尿剂,17,589名(12%)为袢利尿剂,33,172名(22%)为钙通道阻滞剂,53,772名(36%)为β受体阻滞剂。接受噻嗪类利尿剂和钙通道阻滞剂的患者基线血压最高。接受袢利尿剂的患者更可能患有晚期CKD或心力衰竭。在中位(四分位距)随访1282(621, 1979)天期间,与噻嗪类利尿剂相比,钙通道阻滞剂的心血管事件风险较高,调整后的风险比(aHR)为1.18(95% CI 1.15-1.22),β受体阻滞剂aHR为1.63(95% CI 1.58-1.67),袢利尿剂aHR为1.97(95% CI 1.90-2.04)。钙通道阻滞剂的复合肾脏结局风险也较高,aHR为1.42(95% CI 1.33-1.52),β受体阻滞剂aHR为1.13(95% CI 1.06-1.21),袢利尿剂aHR为1.98(95% CI 1.83-2.15)。在ACEi/ARB治疗基础上加用噻嗪类利尿剂而非钙通道阻滞剂、β受体阻滞剂或袢利尿剂,与CKD患者有利的临床结局相关。
基础研究 (5篇)
Diabetic kidney disease (DKD) remains the leading cause of chronic kidney disease (CKD) worldwide despite advances in glycemic control, blood pressure management, and renin-angiotensin-aldosterone system blockade. The introduction of sodium-glucose cotransporter 2 (SGLT2) inhibitors has fundamentally changed the management of CKD by consistently reducing kidney disease progression and cardiovascular events in patients both with and without diabetes. These findings indicate that the benefits of SGLT2 inhibition extend beyond glucose lowering and reflect broader effects on cardiorenal physiology. This review examines the pharmacological mechanisms underlying SGLT2 inhibitor-mediated kidney protection, integrating experimental evidence with findings from major clinical outcome trials. Current evidence supports a hierarchical mechanistic model in which inhibition of proximal tubular sodium-glucose reabsorption represents the primary pharmacological event, restoring tubule-glomerular feedback, reducing intraglomerular pressure, and lowering tubular transport workload. These upstream hemodynamic and metabolic effects are thought to initiate downstream improvements in kidney oxygen balance, mitochondrial function, inflammation, oxidative stress, and fibrosis, although the relative contribution of these pathways remains incompletely defined. We further examine how contemporary clinical trials validate this mechanistic framework across diverse CKD populations, including patients with and without diabetes and across a broad range of kidney function and albuminuria. Finally, we discuss the implications of these findings for phenotype-specific treatment strategies, rational combination therapy with complementary kidney-protective agents, and future directions in biomarker-guided precision medicine. Collectively, current evidence supports SGLT2 inhibitors as integrated cardiorenal therapies that modify fundamental determinants of CKD progression and provide the pharmacological foundation of contemporary kidney-protective treatment.
中文摘要:尽管在血糖控制血压管理和肾素血管紧张素醛固酮系统阻断方面取得进展糖尿病肾病仍是全球慢性肾脏病的主要病因钠葡萄糖协同转运蛋白2抑制剂的引入通过持续减少有或无糖尿病患者肾脏疾病进展和心血管事件从根本上改变了慢性肾脏病的管理这些发现表明钠葡萄糖协同转运蛋白2抑制的益处超出了降糖范围并反映了对心肾生理更广泛的影响本综述考察了钠葡萄糖协同转运蛋白2抑制剂介导肾脏保护的药理学机制整合了实验证据与主要临床结果试验的发现当前证据支持一种分层机制模型其中近端小管钠葡萄糖重吸收的抑制代表主要的药理学事件恢复小管肾小球反馈降低肾小球内压并降低小管运输负荷这些上游血流动力学和代谢效应被认为启动了下游肾脏氧平衡线粒体功能炎症氧化应激和纤维化的改善尽管这些通路的相对贡献仍未完全明确我们进一步考察了当代临床试验如何在包括有或无糖尿病以及广泛肾功能和白蛋白尿范围在内的不同慢性肾脏病人群中验证这一机制框架最后我们讨论了这些发现对表型特异性治疗策略与互补肾脏保护药物的合理联合疗法以及生物标志物指导的精准医学未来方向的影响总体而言当前证据支持钠葡萄糖协同转运蛋白2抑制剂作为整合的心肾治疗药物改变慢性肾脏病进展的根本决定因素并提供当代肾脏保护治疗的药理学基础
Proteome-wide Mendelian randomization (PWMR) provides a genetic framework to identify circulating proteins causally implicated in chronic kidney disease (CKD) and prioritize them for drug discovery. However, the diverse etiologies of CKD and clinical presentations make it difficult to translate proteomic findings into actionable targets. Here, we studied protein associations with longitudinal kidney outcomes, CKD subtypes, and phenome-wide traits to identify proteins that are causally relevant and pharmacologically actionable. We performed a PWMR study using cis-pQTLs as genetic instruments for 2807 circulating proteins from four proteogenomic cohorts (ARIC, Fenland, deCODE, and UK Biobank) and tested their effects across four kidney outcomes (eGFR, incident CKD, incident kidney failure, annualized eGFR slope) in up to 464,631 of Million Veteran Program participants. Proteins meeting proteome-wide significance underwent sensitivity testing, Bayesian colocalization, and external replication in CKDGen Consortium information. The same instruments were re-tested against nine diagnosis code-defined CKD subtypes using genome wide association studies meta-analysis across the Million Veteran Program participants, UK Biobank, and FinnGen, and against 1020 phecodes to distinguish kidney-restricted from systemic effects. Druggability was evaluated using ChEMBL annotations layered onto high-confidence STRING protein-protein interaction networks. We identified 93 proteins with proteome-wide significance, and twelve remained robust across sensitivity testing (ANGPTL3, FAM213A, GCKR, GSTA1, IDI2, INHBA, INHBC, MANBA, MICB, MST1, NRG4, UMOD). Forty-seven proteins mapped to at least one of nine kidney disease subtypes, with distinct patterns across diabetic, hypertensive, and glomerular kidney diseases. Phenome-wide testing separated seven proteins with kidney-restricted associations from those with broader systemic effects. Thirty-four proteins were pharmacologic targets, nominating candidates such as IL-1 pathway blockade for diabetic kidney disease and ANGPTL3 inhibition for podocyte protection. Our integrative PWMR framework resolves circulating protein targets across CKD etiologies, separates kidney-restricted from systemic effects, and delivers actionable targets that may accelerate therapeutic innovation for CKD. About one-third of the 93 proteins could be targeted with existing or investigational medications.
中文摘要:蛋白质组学孟德尔随机化(PWMR)为识别与慢性肾脏病(CKD)存在因果关系的循环蛋白并优先筛选药物发现靶点提供了遗传框架。然而,CKD病因的多样性和临床表现使得将蛋白质组学发现转化为可操作的靶点变得困难。本研究通过考察蛋白质与纵向肾脏结局、CKD亚型及全表型特征的关系,旨在识别具有因果相关性和药理学可操作性的蛋白。我们利用来自四个蛋白质基因组队列(ARIC、Fenland、deCODE和UK Biobank)的2807种循环蛋白的顺式pQTL作为遗传工具,进行了PWMR研究,并在多达464,631名退伍军人百万计划参与者中测试了它们对四种肾脏结局(eGFR、新发CKD、新发肾衰竭、年eGFR斜率)的影响。达到蛋白质组学显著性水平的蛋白接受了敏感性测试、贝叶斯共定位以及在CKDGen联盟数据中的外部验证。相同的工具变量在退伍军人百万计划参与者、UK Biobank和FinnGen中通过全基因组关联研究荟萃分析,针对九种由诊断代码定义的CKD亚型进行了重新测试,并针对1020个phecodes进行测试,以区分肾脏特异性效应与全身性效应。利用叠加在高置信度STRING蛋白质相互作用网络上的ChEMBL注释评估了药物的可靶向性。我们鉴定出93种具有蛋白质组学显著性的蛋白,其中十二种在敏感性测试中保持稳健(ANGPTL3、FAM213A、GCKR、GSTA1、IDI2、INHBA、INHBC、MANBA、MICB、MST1、NRG4、UMOD)。四十七种蛋白映射到至少一种肾脏疾病亚型,在糖尿病性、高血压性和肾小球性肾病中表现出不同的模式。全表型测试将七种具有肾脏特异性关联的蛋白与具有更广泛全身性效应的蛋白区分开来。三十四种蛋白是药理学靶点,提名了如IL-1通路阻断用于糖尿病肾病和ANGPTL3抑制用于足细胞保护等候选方案。我们的整合PWMR框架解决了CKD病因中的循环蛋白靶点,区分了肾脏特异性与全身性效应,并提供了可操作的靶点,可能加速CKD的治疗创新。在93种蛋白中,约三分之一可用现有或研究中的药物进行靶向。
Urinary proteins are valuable biomarkers for physiological processes and early detection/monitoring of kidney diseases. However, comprehensive quantification and characterization of the urine proteome using a high-throughput platform remains limited. Using the affinity-based Olink Explore 3072 proteomics assay, we quantified 2868 proteins in urine samples from 1268 participants of the German Chronic Kidney Disease (GCKD) study. Protein detectability in urine, defined as the percentage of samples with measurements above the limit of detection, showed a bimodal distribution: 659 (23%) proteins had high (over 80%) and 1336 proteins (47%) had low (under 20%) detectability, with stable detectability across strata of albuminuria and kidney function. More than 95% of highly detectable proteins had previously been identified in urine by mass spectrometry. Highly detectable proteins were enriched for extracellular, exosomal, and cell surface localization, and for expression in hepatocytes, immune cells and kidney proximal tubule cells. Comparison with plasma detectability from the UK Biobank Pharma Proteomics Project identified proteins of likely kidney origin, including LRP2 (megalin) and NPHS2 (podocin). In a multivariable adjusted model of 13 clinical variables, albuminuria and an individual's sex showed significant associations with 779 and 670 proteins, respectively. Specific chronic kidney disease etiologies showed associations with 105 proteins, although etiology explained only a small proportion of protein variance. Correlation analysis revealed biologically meaningful protein clusters reflecting shared cellular compartments, tissue of origin, and molecular interactions. Large-scale urine proteomic profiling using a high-multiplex affinity-based platform captures biologically meaningful molecular variation associated with clinical variables and chronic kidney disease, providing a valuable resource for biomarker discovery and future targeted studies.
中文摘要:尿液蛋白是生理过程及肾脏疾病早期检测与监测的有价值生物标志物。然而,利用高通量平台对尿液蛋白质组进行全面的定量和表征仍然有限。本研究采用基于亲和力的Olink Explore 3072蛋白质组学检测方法,对德国慢性肾脏病(GCKD)研究中1268名参与者的尿液样本中的2868种蛋白质进行了定量。尿液中蛋白质的可检测性定义为测量值高于检测限的样本百分比,呈现双峰分布:659种(23%)蛋白质具有高(超过80%)可检测性,1336种(47%)蛋白质具有低(低于20%)可检测性,且在不同白蛋白尿和肾功能分层中可检测性保持稳定。超过95%的高可检测性蛋白质此前已通过质谱法在尿液中被鉴定。高可检测性蛋白质富集于细胞外、外泌体和细胞表面定位,并在肝细胞、免疫细胞和肾近端小管细胞中表达。通过与英国生物银行药物蛋白质组学项目中的血浆可检测性进行比较,识别出可能源自肾脏的蛋白质,包括LRP2(megalin)和NPHS2(podocin)。在包含13个临床变量的多变量调整模型中,白蛋白尿和个人性别分别与779种和670种蛋白质显示出显著关联。特定的慢性肾脏病病因与105种蛋白质相关,尽管病因仅解释了蛋白质变异的很小一部分。相关性分析揭示了具有生物学意义的蛋白质簇,反映了共享的细胞区室、组织来源及分子相互作用。利用高多重亲和力平台进行的大规模尿液蛋白质组谱分析捕获了与临床变量和慢性肾脏病相关的具有生物学意义的分子变异,为生物标志物发现和未来的靶向研究提供了宝贵资源。
Dysregulated amino acid metabolism is a prominent feature after acute kidney injury (AKI), but its contribution to chronic kidney disease (CKD) progression remains unclear. The therapeutic potential of targeting these metabolic alterations also remains poorly understood. Quantification of 20 circulating L-amino acids revealed that L-alanine (Ala) showed the most pronounced reduction in patients with cardiac surgery-associated AKI and renal ischemia-reperfusion injury (IRI) mice. Notably, supplementation of exogenous Ala attenuated the AKI-to-CKD transition in IRI mice. Mechanistically, Ala restored monocarboxylate transporter 2 (MCT2) expression by preventing heterogeneous nuclear ribonucleoprotein M (hnRNPM)-mediated destabilization of D-box binding protein (DBP) mRNA. Subsequently, DBP was identified as a transcriptional regulator of MCT2 and enhanced its transcription by directly binding to its promoter region. Furthermore, renal tubular epithelial cell (RTEC)-specific deletion of MCT2 blunted Ala-mediated restoration of mitochondrial oxidative metabolism and renal protection. These findings reveal a mechanism by which Ala promotes tubular metabolic recovery and provide preclinical evidence supporting further evaluation of Ala supplementation to limit AKI-to-CKD progression after cardiac surgery.
中文摘要:氨基酸代谢失调是急性肾损伤(AKI)后的显著特征,但其对慢性肾脏病(CKD)进展的贡献尚不明确。靶向这些代谢改变的治疗潜力也知之甚少。对20种循环L-氨基酸的定量分析显示,在心脏手术相关AKI患者和肾缺血再灌注损伤(IRI)小鼠中,L-丙氨酸(Ala)的减少最为显著。值得注意的是,补充外源性Ala减轻了IRI小鼠从AKI向CKD的过渡。机制上,Ala通过防止异质性核糖核蛋白M(hnRNPM)介导的D盒结合蛋白(DBP)mRNA不稳定,恢复了单羧酸转运蛋白2(MCT2)的表达。随后发现DBP是MCT2的转录调节因子,并通过直接结合其启动子区域增强其转录。此外,肾小管上皮细胞(RTEC)特异性敲除MCT2削弱了Ala介导的线粒体氧化代谢恢复和肾脏保护作用。这些发现揭示了Ala促进小管代谢恢复的机制,并为进一步评估补充Ala以限制心脏手术后AKI向CKD进展提供了临床前证据。
Chronic kidney disease (CKD) is increasing rapidly in African populations, yet its molecular determinants remain poorly characterised. While epigenome-wide studies have been largely confined to high-income settings, comparable longitudinal epigenetic data from African populations are scarce, despite distinct genetic and environmental contexts. We conducted a longitudinal epigenome-wide study of CKD in an African population, integrating DNA methylation and gene expression to identify epigenetic changes associated with CKD and related kidney function decline. DNA methylation was profiled using the Illumina EPIC (850K) array in 274 Ghanaian participants from the RODAM-Prospective cohort (92 incident CKD cases and 182 matched controls), providing 548 DNA methylation observations across baseline and ∼6-year follow-up, with high-quality DNA methylation data available at both timepoints. Epigenome-wide association studies (EWAS) were performed for incident CKD, change in estimated glomerular filtration rate (ΔeGFR), and change in urinary albumin-to-creatinine ratio (ΔACR), adjusting for demographic, clinical, and technical covariates. Differentially methylated regions (DMRs) were identified using bumphunter with family-wise error rate control. Differential gene expression (RNA-seq) analyses were conducted, followed by covariate-adjusted expression quantitative trait methylation (eQTM) analyses to link methylation with gene expression. At baseline, significant differentially methylated positions (DMPs) were detected at INF2 (incident CKD), CLIP4 (ΔeGFR), and TMEM109 (ΔACR), alongside DMRs at HLA-DPB1 and SH2D1B (incident CKD) and ZFP57 and OR2T11 (ΔACR). At follow-up, a progression-related DMR in C4orf39/TRIM61 (ΔACR) was identified, with recurrent signals at hypermethylated HLA-DPB1 and hypomethylated ZFP57 and OR2T11 across timepoints. Integrative eQTM analysis revealed methylation-expression associations at recurrent loci including ZFP57, HLA-DRB5, SLC39A4, and SPATC1L, with predominantly inverse associations at ZFP57, HLA-DRB5, and SLC39A4, highlighting associations with metabolic and immune regulatory pathways. We identified epigenetic changes associated with incident CKD and kidney function decline in an African population. These methylation signals, supported by gene expression patterns, highlight immune and kidney-related pathways associated with CKD risk and progression. Our findings provide a foundation for future studies investigating the potential of epigenetic markers in CKD risk stratification and prevention in African populations. European Commission; European Research Council.
中文摘要:慢性肾脏病在非洲人群中的发病率迅速上升,但其分子决定因素尚不明确。尽管表观基因组学研究主要集中在高收入国家,但在具有独特遗传和环境背景的非洲人群中,纵向表观遗传数据依然匮乏。本研究对非洲人群的慢性肾脏病进行了纵向全表观组研究,整合DNA甲基化和基因表达数据,以识别与慢性肾脏病及相关肾功能下降相关的表观遗传改变。利用Illumina EPIC阵列对RODAM前瞻性队列中的274名加纳参与者(92例新发慢性肾脏病病例和182名匹配对照)进行DNA甲基化谱分析,提供了基线和约6年随访期间的548个DNA甲基化观测值,且两个时间点均拥有高质量的DNA甲基化数据。针对新发慢性肾脏病、估算肾小球滤过率变化及尿白蛋白肌酐比值变化进行了表观基因组关联研究,并调整了人口统计学、临床和技术协变量。使用bumphunter算法控制族系误差率以识别差异甲基化区域。进行了差异基因表达分析,随后进行协变量调整的表达数量性状甲基化分析以关联甲基化与基因表达。在基线时,检测到INF2位点与新发慢性肾脏病相关、CLIP4位点与估算肾小球滤过率变化相关、TMEM109位点与尿白蛋白肌酐比值变化相关的显著差异甲基化位点,以及HLA-DPB1和SH2D1B位点与新发慢性肾脏病相关、ZFP57和OR2T11位点与尿白蛋白肌酐比值变化相关的差异甲基化区域。在随访期间,发现C4orf39/TRIM61位点存在进展相关的差异甲基化区域,并在不同时间点重复出现HLA-DPB1高甲基化和ZFP57及OR2T11低甲基化的信号。整合性表达数量性状甲基化分析揭示了包括ZFP57、HLA-DRB5、SLC39A4和SPATC1L在内的重复位点存在甲基化与表达的关联,其中ZFP57、HLA-DRB5和SLC39A4主要呈现负相关,突显了其与代谢和免疫调节通路的关联。我们在非洲人群中识别出与新发慢性肾脏病和肾功能下降相关的表观遗传改变。这些得到基因表达模式支持的甲基化信号突显了与慢性肾脏病风险和进展相关的免疫及肾脏相关通路。我们的发现为未来研究表观遗传标志物在非洲人群慢性肾脏病风险分层和预防中的潜力奠定了基础。
2急性肾损伤 AKI (6篇)
临床研究 (2篇)
Cigarette smoking is a modifiable risk factor for kidney disease, but the degree to which smoking cessation reduces acute kidney injury (AKI) remains unclear. This study evaluated whether smoking status and duration of smoking cessation were associated with AKI risk. Population-based retrospective cohort study. 1,151,722 adults without evidence of kidney disease who had a health examination recorded in the Korean National Health Insurance Service (NHIS) database between 2009 and 2013 and who completed at least three prior biennial health examinations subsequent to 2002 that included assessment of smoking status. Smoking status and duration of sustained smoking cessation. Incident hospitalized AKI defined by ICD-10 codes N17.0-N17.9 taken from inpatient administrative claims data. Crude incidence rates and multivariable cause-specific hazard models estimated adjusted hazard ratios (HRs). The cohort included 885,299 never smokers, 55,391 quitters, and 211,032 current smokers. A total of 11,972 study participants experienced an incident hospitalization for AKI occurring over a mean follow-up of 10.73 years. Among quitters, the crude AKI incidence was highest in those whose smoking cessation was less than 2 years in duration and declined with progressively longer durations. In the multivariable-adjusted analysis, never smokers had a significantly lower AKI risk than current smokers (adjusted HR 0.64, 95% CI 0.60-0.68). Among quitters, adjusted HRs decreased progressively with longer durations of smoking cessation (P for trend <0.001). Observational design, self-reported smoking status, inability to update smoking status during follow-up, claims-based AKI ascertainment, and a single-ethnicity population. The risk of AKI was highest in current smokers and lowest in never smokers. Sustained smoking cessation was associated with a lower risk of hospitalized AKI with longer durations of smoking cessation being associated with less risk. These findings support long-term smoking cessation as an important kidney-protective strategy.
中文摘要:吸烟是可干预的肾脏疾病危险因素,但戒烟对降低急性肾损伤(AKI)风险的程度尚不明确。本研究评估了吸烟状态及戒烟持续时间与AKI风险的关系。这是一项基于人群的回顾性队列研究。研究对象为2009至2013年间在韩国国民健康保险服务(NHIS)数据库中有健康体检记录且无肾脏疾病证据的1,151,722名成年人,这些人在2002年之后的至少三次每两年一次的健康检查中完成了吸烟状态评估。主要指标为吸烟状态和持续戒烟持续时间。AKI事件定义为根据住院行政索赔数据中的ICD-10代码N17.0-N17.9确定的入院AKI。采用粗发病率和多变量特定原因风险模型估算调整后的风险比(HR)。队列包括885,299名从不吸烟者、55,391名戒烟者和211,032名当前吸烟者。在平均随访10.73年间,共有11,972名研究参与者经历了AKI入院事件。在戒烟者中,戒烟持续时间不足2年的粗AKI发病率最高,并随持续时间延长而下降。在多变量调整后分析中,从不吸烟者的AKI风险显著低于当前吸烟者(调整HR 0.64,95% CI 0.60-0.68)。在戒烟者中,随着戒烟持续时间的延长,调整后的HR呈进行性下降(趋势P值<0.001)。研究局限性包括观察性设计、自我报告的吸烟状态、随访期间无法更新吸烟状态、基于索赔数据的AKI识别以及单一族裔人群。AKI风险在当前吸烟者中最高,在从不吸烟者中最低。持续戒烟与较低的住院AKI风险相关,且戒烟持续时间越长,风险越低。这些发现支持长期戒烟作为重要的肾脏保护策略。
Mechanical circulatory support (MCS) devices, including intra-aortic balloon pumps, micro-axial flow pumps, venoarterial extracorporeal membrane oxygenation, and ventricular assist devices, have become increasingly common in managing advanced heart failure and cardiogenic shock. Acute kidney injury (AKI) occurs in up to 85% of MCS patients, with 30-45% treated with kidney replacement therapy (KRT). Continuous KRT (CKRT) is generally preferred in this population due to superior hemodynamic tolerability and precise volume control. However, providing CKRT to MCS patients presents unique challenges, including securing a functional vascular access, circuit integration considerations, dual-device blood flow optimization, and anticoagulation management. This review provides practical guidance for nephrologists caring for patients treated with both MCS and CKRT. We describe current MCS technologies and discuss evidence-based approaches to CKRT prescription including modality selection, timing of initiation, vascular access techniques, and anticoagulation strategies. We also address volume management, safety monitoring, and troubleshooting common complications. Despite high short-term mortality, many survivors achieve renal recovery by hospital discharge, emphasizing the importance of optimized CKRT delivery in this complex population.
中文摘要:机械循环支持(MCS)设备,包括主动脉内球囊泵、微轴流泵、静脉动脉体外膜肺氧合及心室辅助装置,在管理晚期心力衰竭和心源性休克中的应用日益广泛。高达85%的MCS患者会发生急性肾损伤(AKI),其中30-45%接受肾脏替代治疗(KRT)。由于具有更好的血流动力学耐受性和精确的容量控制能力,连续肾脏替代治疗(CKRT)通常为该人群的首选方案。然而,为MCS患者提供CKRT面临独特挑战,包括确保功能性血管通路、回路整合考量、双设备血流优化及抗凝管理。本综述为同时接受MCS和CKRT治疗的患者的肾病学家提供实用指导。我们描述了当前的MCS技术,并讨论了基于证据的CKRT处方方法,包括模式选择、启动时机、血管通路技术及抗凝策略。我们还探讨了容量管理、安全监测以及常见并发症的处理。尽管短期死亡率较高,但许多幸存者在出院时实现了肾脏功能恢复,强调了在该复杂人群中优化CKRT实施的重要性。
基础研究 (4篇)
Sepsis-associated acute kidney injury (SA-AKI) is a severe condition characterized by dysregulated inflammatory responses. Transfer RNA-derived small RNAs (tsRNAs), including transfer RNA-derived fragments (tRFs) and transfer RNA halves (tiRNAs), have emerged as regulators of pathological processes in the kidney. However, their roles in SA-AKI remain unclear. To help define this, tRF and tiRNA sequencing was conducted to screen dysregulated tsRNAs in lipopolysaccharide (LPS)-induced SA-AKI in male C57BL/6J mouse kidneys. tiRNA-1:34-Asp-GTC-2 (tiRNA-Asp) was identified as a potential tsRNA candidate. Its expression was quantified using qRT-PCR and its localization was examined by fluorescence in situ hybridization. tiRNA-Asp was silenced in vivo using the antagomir to assess its function in LPS-induced AKI. The biodistribution of Cy7-labeled tiRNA-Asp antagomir was assessed by in vivo and ex vivo fluorescence imaging. Mouse kidney tubular epithelial cells were transfected with tiRNA-Asp mimics or inhibitors to evaluate its pro-inflammatory effects. RNA-seq, dual-luciferase reporter assays, RNA pulldown assays, and rescue experiments were performed to identify downstream targets and elucidate the mechanisms of tiRNA-Asp. tiRNA-Asp showed the most pronounced upregulation in SA-AKI kidneys and was predominantly localized in tubular epithelial cells. It was consistently upregulated across different AKI models. In vivo inhibition of tiRNA-Asp with antagomir alleviated LPS- and ischemia-induced inflammatory responses and kidney injury while suppressing nuclear factor-κB (NF-κB) activation. In kidney tubular epithelial cells, tiRNA-Asp overexpression promoted NF-κB activity and enhanced inflammatory cytokine expression, whereas tiRNA-Asp knockdown suppressed NF-κB activation and reduced cytokine production. Mechanistically, sucrose nonfermenting-related kinase (SNRK), a key anti-inflammatory regulator, was identified as a direct target of tiRNA-Asp. tiRNA-Asp enhanced NF-κB activation and inflammatory responses by downregulating SNRK expression. Angiogenin and ribonuclease inhibitor 1 are associated with tiRNA-Asp biogenesis during sepsis. Our study reveals a novel pro-inflammatory tiRNA involved in the pathogenesis of SA-AKI and demonstrates that the tiRNA-Asp/SNRK/NF-κB pathway may represent a potential therapeutic target for sepsis-induced inflammation and AKI.
中文摘要:脓毒症相关急性肾损伤SA-AKI是一种以炎症反应失调为特征的严重疾病。转移RNA衍生小RNAtsRNAs包括tRF和tiRNA已成为肾脏病理过程的调节因子但其作用尚不明确。本研究通过测序筛选脂多糖LPS诱导的SA-AKI小鼠肾脏中差异表达的tsRNA鉴定出tiRNA-1:34-Asp-GTC-2即tiRNA-Asp作为潜在候选分子。qRT-PCR定量及荧光原位杂交显示tiRNA-Asp在SA-AKI肾脏中显著上调且主要定位于肾小管上皮细胞并在不同AKI模型中持续高表达。体内敲低实验表明抑制tiRNA-Asp可减轻LPS及缺血诱导的炎症反应和肾损伤并抑制NF-κB活化。体外细胞实验证实过表达tiRNA-Asp促进NF-κB活性及炎性细胞因子表达而敲低则抑制NF-κB活化并减少细胞因子产生。机制研究表明SNRK作为关键抗炎调节因子是tiRNA-Asp的直接靶点tiRNA-Asp通过下调SNRK表达增强NF-κB活化和炎症反应。此外血管生成素和核糖核酸酶抑制剂1与脓毒症期间tiRNA-Asp的生物合成相关。本研究揭示了一种参与SA-AKI发病机制的新型促炎tiRNA并表明tiRNA-Asp/SNRK/NF-κB通路可能是治疗脓毒症诱导的炎症和AKI的潜在靶点。
Colistin is an indispensable last-line antibiotic against multidrug-resistant Gram-negative infections, but its use is limited by dose-dependent acute kidney injury (AKI) with proximal tubular damage. Although oxidative stress is implicated, how it translates into tubular injury remains poorly defined, and antioxidant therapy alone shows limited efficacy. We investigated whether ultrasmall copper nanoparticles (Cu NPs), which approach the glomerular filtration threshold and accumulate in renal tubules, protect against colistin nephrotoxicity, using human proximal tubular epithelial HK-2 cells (colistin 200 µg/mL; Cu NPs 200 ng/mL) and female C57BL/6 mice (colistin 30 mg/kg/day; Cu NPs 250 µg/kg twice weekly). In HK-2 cells, colistin induced apoptosis, excess cytosolic and mitochondrial superoxide, mitochondrial fission, and dysregulated autophagy with LC3B accumulation and impaired flux, alongside Akt/GSK3β and mTOR suppression and excessive nuclear TFEB translocation. Pharmacological TFEB activation aggravated injury, indicating that maladaptive autophagy contributes to tubular death. Cu NPs scavenged these oxidants, reactivated Akt/GSK3β/mTOR signaling, and restored productive autophagic flux without suppressing nuclear TFEB, reducing apoptosis and preserving mitochondrial integrity, whereas N-acetylcysteine failed to reproduce these signaling effects. Autophagic flux, rather than the absolute level of nuclear TFEB, therefore determined tubular outcome. Cu NPs accumulated preferentially in the kidney and were protective at sub-toxic doses; in vivo, they attenuated tubular injury and apoptosis and modulated autophagy-related signaling, although functional renal improvement was not demonstrated. Thus, Cu NPs attenuate colistin-induced tubular injury by modulating the Akt/GSK3β/mTOR-TFEB axis and restoring autophagic homeostasis rather than acting solely as antioxidants, supporting their potential as a nephroprotective strategy.
中文摘要:多粘菌素是治疗多重耐药革兰阴性菌感染的不可或缺的最后防线抗生素,但其应用受限于剂量依赖性急性肾损伤及近端小管损伤。尽管氧化应激参与其中,但其转化为小管损伤的机制尚不明确,且单一抗氧化疗法疗效有限。本研究利用人近端小管上皮HK-2细胞(多粘菌素200微克/毫升;铜纳米颗粒Cu NPs 200纳克/毫升)和雌性C57BL/6小鼠(多粘菌素30毫克/公斤/天;Cu NPs 250微克/公斤每周两次),探究了接近肾小球滤过阈值并在肾小管中蓄积的超小铜纳米颗粒是否对多粘菌素肾毒性具有保护作用。在HK-2细胞中,多粘菌素诱导细胞凋亡、胞质及线粒体超氧化物过量、线粒体分裂以及伴有LC3B积累和通量受损的自噬失调,同时伴随Akt/GSK3β和mTOR抑制及TFEB过度核转位。药理学激活TFEB加重了损伤,表明适应性不良的自噬参与了小管死亡。Cu NPs清除了这些氧化剂,重新激活了Akt/GSK3β/mTOR信号通路,恢复了有效的自噬通量而未抑制TFEB核定位,从而减少细胞凋亡并维持线粒体完整性,而N-乙酰半胱氨酸未能重现这些信号效应。因此,自噬通量而非TFEB核绝对水平决定了小管结局。Cu NPs在肾脏中优先蓄积并在亚毒性剂量下具有保护作用;体内实验显示其减轻了小管损伤和细胞凋亡并调节了自噬相关信号,但未证实肾功能改善。综上,Cu NPs通过调节Akt/GSK3β/mTOR-TFEB轴并恢复自噬稳态而非仅作为抗氧化剂来减轻多粘菌素诱导的小管损伤,支持其作为一种肾保护策略的潜力。
Intracellular metal ion homeostasis, particularly the precise regulation of mitochondrial iron and calcium, is essential for maintaining energy metabolism and cell survival. Once disrupted, iron-mediated oxidative reactions and calcium overload mutually amplify, rapidly leading to mitochondrial dysfunction and cellular injury. In acute kidney injury (AKI), this mitochondria-centered iron-calcium imbalance represents a critical pathological axis driving oxidative stress, programmed cell death, and inflammation. However, effective therapies that coordinately regulate both processes are not yet available. Herein, we developed a polyvinylpyrrolidone (PVP)-coated Mg-Fe cyanometallate framework nanozyme (MFC) to calibrate iron-calcium homeostasis in AKI. The PVP coating facilitates its interaction with the highly expressed Megalin receptor in renal proximal tubular epithelial cells, promoting receptor-dependent endocytosis and tubular-targeted delivery. Built on a Prussian blue-like coordination framework, MFC efficiently captures bioactive iron to suppress oxidative stress, while its ion-exchange process concurrently releases Mg2+, acting as a physiological calcium antagonist that regulates mitochondrial calcium homeostasis. By stabilizing mitochondrial structure and function, this strategy suppresses the cascade amplification of cell death and inflammatory signaling, significantly ameliorating renal injury in AKI. This study proposes a therapeutic approach for AKI by rewiring mitochondrial iron-calcium imbalance and offers a design paradigm for multifactorially coupled diseases.
中文摘要:细胞内金属离子稳态,特别是线粒体铁和钙的精确调控,对于维持能量代谢和细胞生存至关重要。一旦失衡,铁介导的氧化反应与钙超载相互放大,迅速导致线粒体功能障碍和细胞损伤。在急性肾损伤中,这种以线粒体为中心的铁钙失衡代表了驱动氧化应激、程序性细胞死亡和炎症的关键病理轴。然而,目前尚缺乏能协调调节这两种过程的有效疗法。本研究开发了一种聚乙烯吡咯烷酮包覆的Mg-Fe氰基金属有机框架纳米酶(MFC),用于校准急性肾损伤中的铁钙稳态。PVP涂层促进其与高表达的Megalin受体相互作用,促进受体依赖性内吞和近端小管靶向递送。基于类普鲁士蓝配位框架,MFC能有效捕获生物活性铁以抑制氧化应激,同时其离子交换过程释放Mg2+,作为生理性钙拮抗剂调节线粒体钙稳态。通过稳定线粒体结构和功能,该策略抑制了细胞死亡和炎症信号的级联放大,显著改善了急性肾损伤中的肾脏损伤。本研究提出了一种通过重构线粒体铁钙失衡来治疗急性肾损伤的方法,并为多因素耦合疾病提供了设计范式。
Early diagnosis of acute kidney injury (AKI) remains a major clinical challenge due to the delayed and insensitive nature of conventional markers such as serum creatinine. Urinary protein biomarkers, including neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C (CysC), provide earlier and complementary information on kidney injury, but their clinical translation is limited by the lack of rapid, quantitative, and multiplexed point-of-care (POC) diagnostic tests. Here, we report a multiplexed plasmonic-fluor-based lateral flow assay (p-LFA) that enables sensitive, quantitative, and simultaneous detection of NGAL and CysC. By harnessing ultrabright plasmonic-fluor nanolabels and ratiometric fluorescence analysis, the p-LFA achieves picogram-per-milliliter analytical sensitivity comparable to that of the enzyme-linked immunosorbent assay (ELISA). In addition, the simplified assay format enables sample-to-answer times as short as 10 min, while maintaining sensitivity sufficient for accurate AKI detection. Clinical validation using pediatric urine samples demonstrates a strong correlation with ELISA measurements for both biomarkers. Combined analysis of NGAL and CysC significantly improves AKI diagnostic performance, yielding an area under the receiver operating characteristic curve of 0.973 with a clinical sensitivity of 90.9% and specificity of 91.2% in the studied cohort. Furthermore, a low-cost, portable fluorescence reader enables quantitative performance equivalent to benchtop imaging while dramatically reducing instrument cost and complexity. Collectively, this work establishes a scalable and adaptable p-LFA platform that bridges laboratory-grade immunoassays and practical POC diagnostics, offering a promising solution for early AKI detection and multiplexed biomarker analysis in decentralized healthcare settings.
中文摘要:由于血清肌酐等传统标志物存在延迟和敏感性不足的问题,急性肾损伤(AKI)的早期诊断仍面临重大临床挑战。尿蛋白生物标志物如中性粒细胞明胶酶相关脂质运载蛋白(NGAL)和胱抑素C(CysC)可提供更早且互补的肾脏损伤信息,但其临床转化受限于缺乏快速、定量及多重化的即时检测(POC)手段。本研究报道了一种基于等离激元荧光的多重侧向层析试纸条(p-LFA),可实现对NGAL和CysC的灵敏、定量及同步检测。通过利用超亮等离激元荧光纳米标记物和比率荧光分析,该p-LFA达到了皮克每毫升的分析灵敏度,与酶联免疫吸附测定(ELISA)相当。此外,简化的检测流程使样本到结果的时间缩短至10分钟,同时保持了足以准确检测AKI的灵敏度。利用儿科尿液样本进行的临床验证显示,两种生物标志物的检测结果与ELISA测量值呈强相关性。NGAL和CysC的组合分析显著提高了AKI的诊断性能,在研究队列中受试者工作特征曲线下面积达到0.973,临床敏感性为90.9%,特异性为91.2%。此外,低成本便携式荧光读数仪实现了与台式成像设备相当的定量性能,同时大幅降低了仪器成本和复杂性。综上所述,本研究建立了一种可扩展且适应性强的p-LFA平台,桥接了实验室级免疫测定与实用的POC诊断,为分散化医疗环境中的早期AKI检测和多重生物标志物分析提供了有前景的解决方案。
3肾小球疾病 (5篇)
临床研究 (3篇)
Refractory lupus nephritis (LN), particularly mixed class IV + V histology, is the most treatment-resistant subtype. Rituximab (RTX) often results in incomplete B-cell depletion and limited efficacy in refractory patients, whereas CAR-T-cell therapy is associated with substantial risks of lymphodepletion. Here, we report a novel, off-the-shelf immunotherapy combining genetically enhanced allogeneic trifunctional NK cells with RTX without lymphodepleting preconditioning. NK cells were engineered to express NKG2D (targeting stress ligands on autoimmune B cells), high levels of CD16 (for enhanced antibody-dependent cellular cytotoxicity with RTX), and membrane-bound IL-15/IL-15Rα (for in vivo survival). In vitro, these cells selectively killed SLE patient B cells via NKG2D-MICA/B recognition and enhanced ADCC. In NOG mice, the engineered trifunctional NK cells persisted for up to 90 days, with a 30-fold greater peak abundance than unmodified NK cells. This combination was preliminarily validated in a human SLE-PBMC xenograft model. In a first-in-human trial (NCT06676631), two patients with refractory mixed-class LN (IV-G(A/C) + V and IV-G(A) + V), massive proteinuria, hematuria, and multiorgan involvement for whom intensive immunosuppression failed were treated. The therapy was well tolerated and did not cause cytokine release syndrome or neurotoxicity. Both patients achieved rapid B-cell depletion, with proteinuria reductions of 73% and 52%, respectively, and sustained SRI-4 responses, indicating meaningful clinical improvement while being maintained on low-dose steroids. These results provide the first proof of concept that lymphodepletion-free, off-the-shelf, trifunctional NKR-NK immunotherapy is feasible and effective in refractory LN, even in the most challenging subtypes.
中文摘要:难治性狼疮肾炎特别是混合IV加V型组织学是最难治疗的亚型。利妥昔单抗常导致B细胞清除不彻底且疗效有限,而CAR-T细胞疗法与显著的淋巴清除风险相关。本研究报道了一种新型现成免疫疗法,将基因增强的同种三功能NK细胞与利妥昔单抗联合使用且不进行淋巴清除预处理。NK细胞被工程化改造以表达NKG2D(靶向自身免疫B细胞上的应激配体)、高水平的CD16(增强与利妥昔单抗的抗体依赖性细胞介导的细胞毒性)以及膜结合IL-15/IL-15Rα(促进体内存活)。体外实验中,这些细胞通过NKG2D-MICA/B识别选择性杀伤系统性红斑狼疮患者B细胞并增强ADCC。在NOG小鼠中,工程化三功能NK细胞持续存在长达90天,峰值丰度比未修饰NK细胞高30倍。该组合方案在人SLE-PBX异种移植模型中得到了初步验证。在一项首次人体试验NCT06676631中,两名患有难治性混合型LN(IV-G(A/C)加V和IV-G(A)加V)、大量蛋白尿、血尿和多器官受累且强化免疫抑制治疗失败的患者的治疗方案显示该疗法耐受性良好未引起细胞因子释放综合征或神经毒性。两名患者均实现快速B细胞清除,蛋白尿分别减少73%和52%,并维持SRI-4反应表明在低剂量激素维持下具有有意义的临床改善。这些结果提供了首个概念验证证明无淋巴清除的现成三功能NKR-NK免疫疗法在难治性LN甚至最具挑战性的亚型中是可行且有效的。
Glomerular damage is traditionally assessed by measuring urinary protein loss. While both the urinary albumin-creatinine ratio (UACR) and protein-creatinine ratio (UPCR) are used in clinical practice via 24-hour or spot urine samples, a more uniform approach to the assessment of urinary proteins and guidance when and how to assess urinary proteins would facilitate the diagnosis and monitoring of CKD. The United States National Kidney Foundation sponsored a scientific workshop to define optimal methods for the measurement of urinary proteins in April 2025. Based on existing literature, prospective studies and meta-analyses, workshop participants concluded that in general the measurement of urinary albumin is preferred over measurement of total urinary protein for several reasons. Firstly, urinary albumin assays are expected to be internationally standardized beginning in 2027, allowing optimal comparability within laboratories over time and across laboratories. Secondly, optimal pre-analytical handling of urine samples are well documented for urinary albumin unlike protein. Thirdly, urinary albumin concentration shows a moderately stronger association with clinical outcomes compared to urinary total protein, particularly in high-risk individuals. Thus, measurement of urinary albumin concentration should in general be preferred when determining the urinary excretion of proteins in future clinical practice and trials.
中文摘要:传统上通过测量尿蛋白丢失来评估肾小球损伤。尽管在临床实践中常使用24小时或随机尿液样本检测尿白蛋白肌酐比值(UACR)和尿蛋白肌酐比值(UPCR),但更统一的尿蛋白评估方法及何时如何评估尿蛋白的指导原则将有助于慢性肾脏病(CKD)的诊断与监测。美国国家肾脏基金会于2025年4月赞助举办了一次科学研讨会,旨在定义尿液蛋白测量的最佳方法。基于现有文献、前瞻性研究和荟萃分析,与会者得出结论:总体而言,测量尿白蛋白优于测量总尿蛋白,原因如下。首先,预计自2027年起尿白蛋白检测将在国际上实现标准化,从而实现实验室内部及跨实验室随时间的最佳可比性。其次,与蛋白质不同,尿液样本的最佳分析前处理已有充分文献记载。第三,与总尿蛋白相比,尿白蛋白浓度与临床结局的相关性更强,特别是在高危人群中。因此,在未来临床实践和试验中确定尿蛋白排泄量时,通常应优先选择测量尿白蛋白浓度。
In VALIANT (phase 3 trial), pegcetacoplan (C3/C3b inhibitor) demonstrated significant proteinuria reduction at week 26 versus placebo (prespecified primary endpoint), stable eGFR, and glomerular C3 clearance in participants with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. In VALIANT's 26-week randomized controlled period, participants (≥12 years) received subcutaneous pegcetacoplan (n=63) or placebo (n=61) twice weekly plus supportive care. During the 26-week open-label period, all received pegcetacoplan. Here we report prespecified exploratory endpoints during the open-label period. Fifty-nine participants who received pegcetacoplan and 55 who received placebo in the randomized controlled period completed the open-label period. At week 52, the pegcetacoplan-to-pegcetacoplan group maintained the 26-week proteinuria reduction (mean [95% confidence interval (CI)] urine protein-to-creatinine ratio changes from baseline: week 26, -67.1% [-74.9 to -56.8]; week 52, -67.2% [-75.8 to -55.4]). The placebo-to-pegcetacoplan group showed proteinuria changes of 3.2% (-9.6 to 17.9) (26 weeks of placebo), and -53.9% (-64.5 to -40.1) (26 weeks of pegcetacoplan [pegcetacoplan start [week 26] to week 52; post hoc]). In the pegcetacoplan-to-pegcetacoplan group, eGFR changes from baseline (least-squares [LS] mean [95% CI]) were -1.2 mL/min/1.73 m2 (-5.6 to 3.2) (week 26) and -3.7 mL/min/1.73 m2 (-8.9 to 1.6) (week 52). In the placebo-to-pegcetacoplan group, mean (95% CI) eGFR changes from baseline were -7.9 (-11.7 to -4.2) (week 26) and -4.7 (-9.1 to -0.3) (week 52); week-26-to-52 change was +3.0 (-1.0 to 7.1) (post hoc). Post hoc analyses of 52 weeks of pegcetacoplan (n=118) showed proteinuria reduction (geometric mean [95% CI] -63.0% [-69.9 to -54.7]) and eGFR stabilization (LS mean [95% CI] change from realigned baseline, +0.1 [-3.8 to 4.0] mL/min/1.73 m2). No new safety concerns were identified. No encapsulated meningococcal infections, deaths, or allograft losses occurred. Results demonstrate sustained proteinuria reduction and eGFR stabilization after 1 year of pegcetacoplan.
中文摘要:在VALIANT(3期试验)中,pegcetacoplan(C3/C3b抑制剂)在26周时较安慰剂显著降低蛋白尿(预设主要终点),并维持eGFR稳定及清除肾小球C3,受试者为C3肾小球病和原发性免疫复合物膜增生性肾小球肾炎患者。在VALIANT的26周随机对照阶段,≥12岁受试者接受每周两次皮下注射pegcetacoplan(n=63)或安慰剂(n=61)加支持治疗。在随后的26周开放标签阶段,所有受试者均接受pegcetacoplan治疗。此处报告开放标签阶段的预设探索性终点结果。随机对照阶段接受pegcetacoplan的59名受试者和接受安慰剂的55名受试者完成了开放标签阶段。在第52周,pegcetacoplan持续组维持了26周的蛋白尿降低(基线尿蛋白肌酐比变化均值[95%置信区间]:第26周为-67.1%[-74.9至-56.8];第52周为-67.2%[-75.8至-55.4])。安慰剂转pegcetacoplan组显示蛋白尿变化为3.2%(-9.6至17.9)(26周安慰剂),以及-53.9%(-64.5至-40.1)(26周pegcetacoplan,从第26周开始至第52周;事后分析)。在pegcetacoplan持续组中,eGFR较基线的变化(最小二乘均值[95%CI])在第26周为-1.2mL/min/1.73m2(-5.6至3.2),第52周为-3.7mL/min/1.73m2(-8.9至1.6)。在安慰剂转pegcetacoplan组中,eGFR较基线的变化均值(95%CI)在第26周为-7.9(-11.7至-4.2),第52周为-4.7(-9.1至-0.3);第26周至52周的变化为+3.0(-1.0至7.1)(事后分析)。对52周pegcetacoplan治疗(n=118)的事后分析显示蛋白尿降低(几何均值[95%CI]-63.0%[-69.9至-54.7])和eGFR稳定(重新校准基线后的最小二乘均值[95%CI]变化为+0.1[-3.8至4.0]mL/min/1.73m2)。未发现新的安全问题。无封装脑膜炎球菌感染、死亡或移植物丢失发生。结果表明,接受pegcetacoplan治疗1年后蛋白尿持续降低且eGFR稳定。
基础研究 (2篇)
PRGN-3008 is a CD19 CAR T cell designed to overcome key limitations in ex vivo and in vivo CAR T manufacturing, cost, safety, and therapeutic durability. Featuring decentralized overnight manufacturing without ex vivo expansion, PRGN-3008 is engineered using a single nonviral transposon to encode CD19 CAR, membrane-bound interleukin-15 (mbIL-15) for improved persistence, PD-1-targeting microRNAs to prevent exhaustion, and an inducible safety switch for controlled in vivo elimination. Safety studies showed low vector copy numbers, favorable integration profile, and efficient CAR T ablation upon safety-switch activation. The combined mbIL-15 expression and PD-1 down-regulation preserved PRGN-3008 polyfunctionality and sustained cytotoxicity across repeated tumor challenges, outperforming nonarmored or singly modified CAR T cells. In xenograft models, overnight-manufactured PRGN-3008 without ex vivo expansion and activation achieved durable tumor clearance, prolonged tumor-free survival, robust antigen dependent expansion, and enrichment of memory T cell phenotypes linked to clinical durability. Notably, PRGN-3008 generated from heavily pretreated patients with systemic lupus erythematosus or lupus nephritis, maintained effector function, resisted terminal differentiation under chronic antigen exposure, and effectively depleted autoreactive B cells in a humanized mouse model. Transcriptomic analysis revealed that the combination of mbIL-15 expression and PD-1 down-regulation enhances the expression of genes associated with bioenergetic pathways, including oxidative phosphorylation, mitochondrial biogenesis, glycolysis, and glutamine utilization, thereby supporting resistance to exhaustion and sustained effector function. Collectively, these data support PRGN-3008 as a clinically translatable, scalable, and controllable CAR T with the potential to expand access to cell therapy across oncology and autoimmune indications.
中文摘要:PRGN-3008是一种CD19嵌合抗原受体T细胞旨在克服体外和体内CAR T制造、成本、安全性和治疗持久性的关键限制。该细胞采用去中心化过夜制造且无需体外扩增,利用单一非病毒转座子编码CD19 CAR、膜结合白细胞介素15以增强持久性、靶向PD-1的微RNA以防止耗竭以及诱导型安全开关以实现体内可控清除。安全性研究表明其载体拷贝数低、整合谱良好且在安全开关激活时能高效清除CAR T细胞。mbIL-15表达与PD-1下调的组合保留了PRGN-3008的多效性并在反复肿瘤挑战中维持细胞毒性优于非装甲或单修饰的CAR T细胞。在异种移植模型中未经体外扩增和激活的过夜制造PRGN-3008实现了持久的肿瘤清除延长了无瘤生存期并促进了与临床持久性相关的记忆T细胞表型富集。值得注意的是源自系统性红斑狼疮或狼疮肾炎重度预处理患者的PRGN-3008在慢性抗原暴露下维持了效应功能抵抗终末分化并在人源化小鼠模型中有效耗竭自身反应性B细胞。转录组分析显示mbIL-15表达与PD-1下调的组合增强了生物能量通路相关基因的表达包括氧化磷酸化线粒体生物发生糖酵解和谷氨酰胺利用从而支持抗耗竭能力和持续的效应功能。这些数据共同支持PRGN-3008作为一种临床可转化可扩展且可控的CAR T细胞具有在肿瘤学和自身免疫适应症中扩大细胞治疗可及性的潜力。
As a major cause of morbidity in systemic lupus erythematosus (SLE), the prognosis of lupus nephritis (LN) critically depends on early detection and timely intervention. However, current diagnostic approaches remain suboptimal: renal biopsy is invasive and unsuitable for longitudinal monitoring, while conventional urine tests lack sensitivity for early-stage disease. Here, we report a molecular imaging strategy designed to target the pathogenic DNA-anti-dsDNA antibody axis for non-invasive detection of LN. We engineered a gallium-68-labeled single-stranded DNA (ssDNA) probe ([68Ga]Ga-NOTA-ssDNA) and evaluated its diagnostic performance and biosafety in the spontaneous MRL/lpr lupus mouse model. The probe showed disease-associated and sustained renal accumulation in 16-week-old diseased MRL/lpr mice, with progressively increasing kidney-to-background contrast. More importantly, [68Ga]Ga-NOTA-ssDNA enabled detection of renal immune complex deposition as early as 10 weeks of age, preceding abnormalities in conventional renal function markers and positive findings in renal histology by approximately two weeks. Mechanistically, the ssDNA backbone demonstrated favorable biocompatibility, without exacerbating autoimmune phenotypes or inducing Toll-like receptor-mediated signaling pathways. In conclusion, this study establishes a robust proof-of-concept for pathology-targeted PET/CT imaging of immune complex deposition. By directly visualizing the disease-driving renal autoantibody deposition at the preclinical stage, prior to overt organ damage, this strategy shifts LN diagnosis to non-invasive, mechanism-based molecular visualization.
中文摘要:狼疮性肾炎是系统性红斑狼疮导致发病的主要原因,其预后高度依赖于早期检测和及时干预。然而,目前的诊断方法仍不理想:肾活检具有侵入性且不适合纵向监测,而常规尿液检测对早期疾病的敏感性不足。在此,我们报告了一种旨在靶向致病性DNA-抗双链DNA抗体轴以实现狼疮性肾炎无创检测的分子成像策略。我们设计了一种镓68标记的单链DNA探针([68Ga]Ga-NOTA-ssDNA),并在自发性MRL/lpr狼疮小鼠模型中评估了其诊断性能和生物安全性。该探针在16周龄患病MRL/lpr小鼠体内表现出疾病相关的持续性肾脏蓄积,且肾脏与背景对比度逐渐增加。更重要的是,[68Ga]Ga-NOTA-ssDNA能够在10周龄时检测到肾免疫复合物沉积,比常规肾功能标志物异常和肾组织学阳性发现早约两周。在机制上,单链DNA骨架表现出良好的生物相容性,不会加剧自身免疫表型或诱导Toll样受体介导的信号通路。总之,本研究确立了针对免疫复合物沉积进行病理靶向PET/CT成像的坚实概念验证。通过在临床前阶段、明显器官损伤之前直接可视化疾病驱动的肾自身抗体沉积,该策略将狼疮性肾炎的诊断转向无创且基于机制的分子可视化。
4基础/转化研究 (2篇)
基础研究 (2篇)
Mitochondrial metabolic defects contribute to chronic kidney disease (CKD) progression, but whether profibrotic signaling directly disrupts adenosine triphosphate (ATP) synthase assembly and promotes tubular epithelial plasticity remains unclear. We examined mitochondrial remodeling during transforming growth factor-β (TGFβ)-induced epithelial-mesenchymal transition (EMT) in renal tubular epithelial cells. Findings were evaluated in mouse kidney fibrosis models and human CKD biopsies. TGFβ reduced ATP synthase (complex V) activity, ATP-linked respiration, and ATP production while increasing mitochondrial membrane potential; complex I-III, II-III, and IV activities were preserved. TGFβ induced zinc finger E-box-binding homeobox 1 (ZEB1)-dependent repression of ATP synthase assembly factor 1 (ATPAF1), impairing ATP synthase assembly. ATPAF1 knockdown reduced ATP synthase assembly and mitochondrial bioenergetic capacity and induced EMT-associated molecular and morphological changes. Conversely, ATPAF1 overexpression restored ATP synthase assembly, ATP production, and respiratory function and attenuated TGFβ-induced EMT-associated changes. ATP supplementation also attenuated TGFβ-induced EMT-associated marker changes. Injured tubules in fibrotic mouse kidneys exhibited reduced ATPAF1 expression and defective ATP synthase assembly, whereas liposome-mediated ATPAF1 plasmid delivery attenuated tubular injury and fibrotic remodeling. In human CKD biopsies, tubular ATPAF1 expression declined with advancing disease and was associated with mitochondrial structural abnormalities. ZEB1-dependent ATPAF1 repression impaired ATP synthase assembly and mitochondrial bioenergetics during TGFβ-induced epithelial plasticity. ATPAF1 perturbation and ATP supplementation findings supported reduced ATP availability as a contributor to EMT-associated changes, rather than elevated mitochondrial membrane potential as a direct driver.
中文摘要:线粒体代谢缺陷促进慢性肾脏病进展,但促纤维化信号是否直接破坏三磷酸腺苷合成酶组装并促进肾小管上皮可塑性尚不明确。本研究考察了转化生长因子β诱导的肾小管上皮细胞上皮间质转化过程中的线粒体重塑。研究结果在小鼠肾脏纤维化模型和人类慢性肾脏病活检样本中进行了评估。转化生长因子β降低了ATP合成酶活性、ATP偶联呼吸和ATP生成,同时增加了线粒体膜电位;而复合体I-III、II-III和IV的活性得以保留。转化生长因子β诱导了锌指E盒结合同源盒1依赖性的ATP合成酶组装因子1表达抑制,从而损害ATP合成酶组装。ATP合成酶组装因子1敲低减少了ATP合成酶组装和线粒体生物能能力,并诱导了上皮间质转化相关的分子和形态学改变。相反,ATP合成酶组装因子1过表达恢复了ATP合成酶组装、ATP生成和呼吸功能,并减轻了转化生长因子β诱导的上皮间质转化相关改变。ATP补充也减轻了转化生长因子β诱导的上皮间质转化标志物改变。纤维化小鼠肾脏中的损伤小管表现出ATP合成酶组装因子1表达降低和ATP合成酶组装缺陷,而脂质体介导的ATP合成酶组装因子1质粒递送减轻了小管损伤和纤维化重塑。在人类慢性肾脏病活检样本中,小管ATP合成酶组装因子1表达随疾病进展而下降,并与线粒体结构异常相关。转化生长因子β诱导的上皮可塑性过程中,锌指E盒结合同源盒1依赖性的ATP合成酶组装因子1抑制损害了ATP合成酶组装和线粒体生物能。ATP合成酶组装因子1扰动和ATP补充的发现支持ATP可用性降低是上皮间质转化相关改变的贡献因素,而非线粒体膜电位升高作为直接驱动因素。
Autoantibody-producing B cells are central drivers of several autoimmune kidney disease, yet current B cell-depleting antibody therapies, such as Rituximab, incompletely suppress pathogenic humoral immunity. Chimeric antigen receptor (CAR) T cell therapy has demonstrated efficacy in compassionate use cases and small clinical trials in autoimmune disorders, but alternative cellular approaches remain underexplored. Here, we developed anti- CD19 CAR macrophages (CAR-Ms) to selectively target CD19+ B cells in an experimental autoimmune glomerulonephritis (EAG) mouse model. The anti-CD19 CAR construct comprising an extracellular anti-CD19 single-chain variable fragment linked to intracellular signaling domains of FcγRI and CD3ζ was cloned into a lentiviral vector and used to transduce murine macrophages. In EAG mice (immunized with human α3(IV)-NC1), CAR-M engraftment and persistence, B cells depletion and kidney injury were assessed following CAR-M administration. In vitro, Anti-CD19 CAR-Ms mediated robust antigen-dependent phagocytosis and efficient depletion of CD19+ B cells. In EAG mice, infused CAR-Ms engrafted in lymphoid organs and inflamed kidneys and persisted for up to 12 weeks, inducing near-complete depletion of CD19+ B cells in blood, lymphoid tissues, and kidney, followed by gradual reconstitution. CAR-M administration significantly improved kidney outcomes, attenuated glomerulosclerosis and tubular injury, and markedly reduced glomerular IgG deposition and circulating autoantibody levels. These effects were associated with selective depletion of mature B cells and plasmablasts, as well as reduced kidney infiltration of T cells and macrophages. CD19-targeted CAR-M immunotherapy achieves sustained B cell depletion and effectively ameliorates murine EAG, highlighting CAR-engineered macrophages as a promising therapeutic strategy for autoimmune kidney disease.
中文摘要:产生自身抗体的B细胞是多种自身免疫性肾脏疾病的核心驱动因素,然而目前使用的B细胞清除抗体疗法(如利妥昔单抗)无法完全抑制致病性体液免疫。嵌合抗原受体T细胞疗法在自身免疫疾病的同情用药案例和小规模临床试验中显示出疗效,但替代性的细胞疗法仍处于探索阶段。本研究开发了抗CD19 CAR巨噬细胞以选择性靶向实验性自身免疫性肾小球肾炎模型中的CD19阳性B细胞。包含胞外抗CD19单链可变片段与FcγRI及CD3ζ胞内信号结构域的抗CD19CAR构建体被克隆至慢病毒载体中,用于转导小鼠巨噬细胞。在EAG小鼠(用人α3(IV)-NC1免疫)中,评估了CAR-M植入与持久性、B细胞清除及肾脏损伤情况。体外实验显示,抗CD19 CAR-M介导了强大的抗原依赖性吞噬作用并有效清除CD19阳性B细胞。在EAG小鼠体内,输注的CAR-M在淋巴器官和炎症肾脏中植入并持续存在长达12周,诱导血液、淋巴组织和肾脏中的CD19阳性B细胞近乎完全清除,随后逐渐重建。CAR-M治疗显著改善了肾脏结局,减轻了肾小球硬化和肾小管损伤,并大幅降低了肾小球IgG沉积和循环自身抗体水平。这些效应与成熟B细胞和浆母细胞的特异性清除以及T细胞和巨噬细胞肾脏浸润减少有关。靶向CD19的CAR-M免疫治疗实现了持续的B细胞清除并有效改善了小鼠EAG,突显了CAR工程化巨噬细胞作为自身免疫性肾脏疾病潜在治疗策略的前景。
5遗传性肾病/囊性 (1篇)
临床研究 (1篇)
Polycystic liver disease (PLD) is the most common extra-renal manifestation of autosomal dominant polycystic kidney disease (ADPKD). Severe PLD may require somatostatin analogs, cyst aspiration or fenestration, partial hepatectomy, and liver transplantation. This study evaluated factors associated with PLD severity, longitudinal total liver volume (TLV) growth, and treatment patterns in a large ADPKD cohort. Retrospective cohort study. A single-center registry including 396 patients with ADPKD who underwent at least one TLV measurement between 2000 and 2023. Demographic, clinical, imaging, genetic, and family history characteristics. Severe PLD defined as height-adjusted TLV >1800 ml/m or receipt of PLD-specific therapies, and annual TLV growth rate. Multivariable logistic regression with adjustment for intrafamilial clustering was used to identify factors associated with severe PLD. Longitudinal TLV growth was evaluated using a mixed-effects model. Among 396 patients (mean age 45 years; 62% women; 88% White; 281 families; mean eGFR 82 ml/min/1.73m2), 115 (29%) had severe PLD. Factors independently associated with severe PLD included older age (P=0.01), female sex (P=0.007), family history of severe liver disease (P<0.001), and lower eGFR (P=0.01). Total kidney volume, genotype, and parity were not significantly associated with severe PLD. Among 195 patients with follow-up measures, the median annual TLV growth rate was 1.83%, with faster growth in women younger than 48 years than in older women (2.99% vs 1.60%, p=0.002). Among patients with severe PLD, 71% received therapy, including somatostatin analogs (48), cyst aspiration/fenestration (8), partial hepatectomy (8), and liver transplantation (44). Single-center retrospective study conducted in a tertiary referral center. Older age, female sex, family history of a severe liver phenotype, and lower eGFR were independently associated with severe PLD in ADPKD. These findings may inform risk stratification and management of patients at risk for progressive PLD.
中文摘要:多囊肝病(PLD)是常染色体显性多囊肾病(ADPKD)最常见的肾外表现。严重的PLD可能需要使用生长抑素类似物、囊肿穿刺或开窗术、部分肝切除以及肝移植。本研究评估了大型ADPKD队列中与PLD严重程度、纵向总肝脏体积(TLV)增长及治疗模式相关的因素。这是一项回顾性队列研究,数据来源于单中心注册库,包含2000年至2023年间至少接受过一次TLV测量的396名ADPKD患者。收集了人口统计学、临床、影像学、遗传学和家族史特征。严重PLD定义为身高调整的TLV大于1800 ml/m或接受了PLD特异性治疗,并计算了年TLV增长率。采用多变量逻辑回归(调整家族内聚类)识别与严重PLD相关的因素。使用混合效应模型评估纵向TLV增长。在396名患者中(平均年龄45岁;女性占62%;白人占88%;281个家庭;平均eGFR为82 ml/min/1.73m2),115名(29%)患有严重PLD。独立与严重PLD相关的因素包括年龄较大(P=0.01)、女性性别(P=0.007)、严重肝病家族史(P<0.001)以及较低的eGFR(P=0.01)。总肾脏体积、基因型和生育次数与严重PLD无显著关联。在195名有随访数据的患者中,中位年TLV增长率为1.83%,48岁以下女性的增长速度快于老年女性(2.99% vs 1.60%,p=0.002)。在患有严重PLD的患者中,71%接受了治疗,包括生长抑素类似物(48例)、囊肿穿刺/开窗术(8例)、部分肝切除(8例)和肝移植(44例)。本研究是在三级转诊中心进行的单中心回顾性研究。年龄较大、女性性别、严重肝病表型的家族史以及较低的eGFR均与ADPKD中的严重PLD独立相关。这些发现可为PLD进展风险患者的风险分层和管理提供依据。
6其他 (1篇)
临床研究 (1篇)
Nephrology fellowship programs in the United States have severe recruitment challenges. Only 65% of clinical positions are filled in the National Residency Matching Program (NRMP), and <50% Accreditation Council for Graduate Medical Education (ACGME)-approved clinical programs are full. 20-30% of fellows are recruited post-match. Ultimately, 80-85% of positions fill, and >60% of fellows are international medical graduates. Despite chronically unfilled positions, the number of NRMP-offered positions and programs has increased, including the number of large programs (>10-fellows). 86% of positions created after 2018 are at large programs (15% of programs; 30% of on-duty fellows). Although recruitment efforts have been modestly successful, barriers include work-life balance, low salaries, patient complexity, and perceived non-competitiveness. Applicant demand is low and increased recruitment unlikely in the short term. We propose a democratically elected program director working group tasked with developing a national management plan that preserves programs, aligns offered positions with NRMP applicant number, and accounts for patient need. The working group could consider a moratorium on increasing program size and number, capping 2-year programs at 10 fellows, NRMP alternatives for programs in rural/underserved areas, and service demands on fellows and faculty. Low morale may contribute to poor recruitment, and nephrology may be perceived as a low prestige specialty because of low applicant to position ratio.
中文摘要:美国肾脏病学培训项目面临严重的招聘挑战。在国家住院医师匹配计划中,仅有65%的临床职位被填补,且不足50%经认证委员会批准临床项目满员。20-30%的住院医师是在匹配后招募的。最终80-85%的职位得到填补,超过60%的住院医师为国际医学毕业生。尽管长期存在未填补的职位,但提供的职位和项目数量仍在增加,包括大型项目(10名以上住院医师)的数量。2018年后创建的职位中,86%位于大型项目(占项目的15%,在岗住院医师的30%)。尽管招聘工作取得了一定成效,但障碍包括工作与生活的平衡、低薪资、患者复杂性以及被认为缺乏竞争力。申请人需求低,短期内增加招聘的可能性不大。我们提议成立一个民选的项目主任工作组,负责制定国家管理计划以保留项目,使提供的职位数量与NRMP申请人数量相匹配,并考虑患者需求。该工作组可考虑暂停增加项目规模和数量,将两年制项目上限设定为10名住院医师,为农村或资源不足地区的项目提供NRMP替代方案,以及评估住院医师和教职员工的任务负担。士气低落可能导致招聘不佳,肾脏病学可能因申请人与职位比例低而被视为低声望专业。